Technical Analysis for SPRB - Spruce Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.76 | -6.06% | -0.05 |
SPRB closed down 6.06 percent on Monday, March 18, 2024, on 3.35 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Volume Surge | Other | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% |
Alert | Time |
---|---|
Possible NR7 | about 13 hours ago |
2x Volume Pace | about 17 hours ago |
1.5x Volume Pace | about 17 hours ago |
3x Volume Pace | about 17 hours ago |
10x Volume Pace | about 17 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/14/2024
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.95 |
52 Week Low | 0.75 |
Average Volume | 1,134,568 |
200-Day Moving Average | 2.44 |
50-Day Moving Average | 3.85 |
20-Day Moving Average | 4.55 |
10-Day Moving Average | 3.82 |
Average True Range | 0.66 |
RSI (14) | 21.26 |
ADX | 33.87 |
+DI | 12.96 |
-DI | 50.09 |
Chandelier Exit (Long, 3 ATRs) | 3.96 |
Chandelier Exit (Short, 3 ATRs) | 2.74 |
Upper Bollinger Bands | 7.72 |
Lower Bollinger Band | 1.38 |
Percent B (%b) | -0.1 |
BandWidth | 139.41 |
MACD Line | -0.56 |
MACD Signal Line | 0.05 |
MACD Histogram | -0.6051 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.88 | ||||
Resistance 3 (R3) | 0.89 | 0.86 | 0.86 | ||
Resistance 2 (R2) | 0.86 | 0.83 | 0.85 | 0.85 | |
Resistance 1 (R1) | 0.81 | 0.81 | 0.79 | 0.80 | 0.85 |
Pivot Point | 0.78 | 0.78 | 0.77 | 0.77 | 0.78 |
Support 1 (S1) | 0.73 | 0.75 | 0.71 | 0.72 | 0.67 |
Support 2 (S2) | 0.70 | 0.73 | 0.69 | 0.67 | |
Support 3 (S3) | 0.65 | 0.70 | 0.66 | ||
Support 4 (S4) | 0.64 |